Resources

2 Resources for

regulus therapeutics

Subscribe to this listing via:
RSS
Email

BNET Resources

Glaxo-Regulus Kicks Off an miRNA Land Grab: GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short. New drug technologies -- or "modalities," as the industry...; Tags: Pharmaceutical Company, miRNA, Regulus Therapeutics, Glaxo, Biotechnology, David P. Hamilton; Blog posts 2008-04-18
Glaxo Boosts Biotech With Regulus Deal: By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK boosted its position in biotech on Thursday by signing a deal that could be worth up to $600 million (303 million pounds) with Regulus Therapeutics, taking it into the hot area of RNA technology. The tie-up covers...; Tags: RNA, Inflammation, Regulus Therapeutics, MicroRNAs, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc.; News items 2008-04-17

Additional Resources

regulus therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...; Articles 2008-05-06
GlaxoSmithKline and regulus therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases: Companies Announce Significant microRNA Therapeutics Collaboration LONDON & PHILADELPHIA & CARLSBAD, Calif. -- GlaxoSmithKline GSK and Regulus Therapeutics LLC Regulus today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus is...; Articles 2008-04-17
regulus therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance: CARLSBAD, Calif. & CAMBRIDGE, Mass. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with GlaxoSmithKline. ...; Articles 2008-04-17

regulus therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today the appointment of Peter S. Linsley, Ph.D., as Chief Scientific Officer. Dr. Linsley has been instrumental...; Articles 2008-02-11
Alnylam Pharmaceuticals Reports Fourth Quarter and 2007 Financial Results: - Completed 2007 with $455.6 Million in Cash and Achieved Over $50 Million in Revenues - - Advanced ALN-RSV01 Program through Phase II Development with Positive Results - - Forged Major Alliance with Roche and Formed Regulus Therapeutics Joint Venture - - Continued Scientific...; Articles 2008-02-07
regulus therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop and commercialize microRNA therapeutics, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., as President and Chief Executive Officer. Dr. Xanthopoulos is...; Articles 2007-12-03
regulus therapeutics Announces Allowance of Key Patent on microRNA Therapeutics for the Treatment of Hepatitis C Virus Infection: New Patent Strengthens Regulus' Leadership in microRNA Therapeutics CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today that the United States Patent and Trademark...; Articles 2007-11-19
Isis, Alnylam Pair To Seek Disease-Fighting Drugs: A promising new approach to targeting human diseases has generated interest from two rival companies accustomed to partnering for the good of science. On Sept. 7, Isis Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. announced the formation of Regulus Therapeutics Inc., a biotechnology startup in Carlsbad focused on commercializing drugs...; Articles 2007-09-17